U.S. markets open in 6 hours 28 minutes

ASLAN Pharmaceuticals Limited (ASLN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.8700+0.0500 (+2.75%)
At close: 4:00PM EST

ASLAN Pharmaceuticals Limited

83 Clemenceau Avenue
No. 12-03 UE Square
Singapore 239920
Singapore
65 6222 4235
http://aslanpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Carl Alan Jason Morton FirthCEO & Exec. DirectorN/AN/A1973
Mr. Kiran Kumar AsarpotaChief Operating OfficerN/AN/A1979
Mr. Ben GoodgerGen. CounselN/AN/A1963
Charlie HsuInvestor Relations DirectorN/AN/AN/A
Chi-Chin WangIR & Corp. Devel. DirectorN/AN/AN/A
Ms. Alison WardChief Devel. OfficerN/AN/AN/A
Mr. Stephen DoyleChief Bus. OfficerN/AN/A1973
Dr. Kenneth KobayashiChief Medical OfficerN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ASLAN Pharmaceuticals Limited, a clinical-stage immunology and oncology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and a small molecule inhibitor targeting oncology. Its partners include Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.

Corporate Governance

ASLAN Pharmaceuticals Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.